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ABSTRACT The formation of hepatitis delta antigen
(HDAg) multimners is required for full biologic activity of this
protein and for replication of the hepatitis delta virus. To
determine the residues responsible for multimerization, three
peptides [612-49, 625-60(Y), 612-60(Y)] from the putative
coiled-coil multimer-forming domain of HDAg were chemi-
cally synthesized and biophysically characterized by circular
dichroic spectroscopy, deuterium-exchange mass spectrome-
try, gel filtration, chemical crosslinking, and ultracentrifu-
gation. By circular dichroism the 50-residue peptide 612-
60(Y) was half-denatured above 80°C and was 97% a-helical
at 5°C and 84% a-helical at 37°C. By deuterium exchange,
peptide 612-60(Y) was 93% a-helical at 25°C. Its high a-he-
licity and melting temperature are due to the formation of an
a-helical multimer consisting of four or more chains. All three
synthetic peptides reacted with human anti-HDAg antibodies
in an enzyme-linked immunosorbent assay, but only peptide
612-60(Y) was detected in a sandwich radioimmunoassay in
which successful antigens must display at least two antibody-
binding sites, which correlates with the ability of this peptide
to form multimers. Peptide 612-60(Y) also interfered with the
self-association of natural HDAg into multimers. These re-
sults have significant practical implications for development
of improved diagnostic tests, antiviral agents, and possibly
even vaccines for prevention of hepatitis delta virus disease.
Leu37, Leu44, and Ile41 variously to glycine, valine, or proline
impaired the replication-related functions of HDAg, presum-
ably by disrupting dimer formation (13, 16, 17). The dimer-
ization of HDAg may involve formation of an a-helical coiled
coil (14, 18, 19), which is characterized by a seven-residue
repeating pattern (heptad) in which the first and fourth
residues are hydrophobic (20). A well-conserved heptad pat-
tern of leucine and isoleucine residues is located within the
N-terminal third of HDAg between Leu27 and Ile58 (Fig. 1A).
However, the computer algorithm of Lupas et al (22) predicts
that the residues from Ile16 to Pro49 should form a coiled coil.
HDAg contains two conserved residues (Gly23 and Pro49) that
may distort an a-helix and thus divide the region spanning
residues 12-60 into three segments: A (Gly'2-Arg24), B (Lys25-
Pro49), and C (Trp50-Lys60) (Fig. 1B).
The structure of the region spanning residues 12-60 of
HDAg was explored by biophysical studies of three synthetic
peptides. A peptide including segments A, B, and C, peptide
812-60(Y), self-associated into stable, immunoreactive a-he-
lical multimers consisting of four or more chains. Shorter
peptides containing segments A and B or B and C had less
a-helical structure, lacked the ability to form multimers, and
were less immunoreactive than peptide 812-60(Y), indicating
that segments A, B, and C are all required for multimer
formation and full antigenicity.
Hepatitis delta virus (HDV) is unique among animal viruses.
This subviral satellite depends upon a coinfecting hepadnavi-
rus for provision of its envelope and often causes severe and
even fatal liver disease in humans (1, 2). The hepatitis delta
antigen (HDAg) is the only protein expressed from its 1.7-kb
circular RNA genome (3). This nuclear phosphoprotein exists
in two forms that have contrasting functions in virus replica-
tion (3-6). The 195-residue small form is a trans-acting
promoter of replication, whereas the 214-residue large form is
a down-regulator of replication and may promote HDV par-
ticle assembly (7-9). Both forms specifically bind HDV RNA,
translocate to the nucleus, and associate into homodimeric,
heterodimeric, and larger multimeric structures (4, 10-14).
Self-association of HDAg into multimers is required for full
biological activity (13, 15) but its mechanism is obscure.
The N-terminal half of HDAg is involved in the formation
of dimers and multimers of HDAg. In vitro translation prod-
ucts representing the N-terminal third of HDAg formed
dimers that were detected by chemical crosslinking (13).
Similarly, chymotryptic fragments containing the N-terminal
76-81 residues ofHDAg recovered from infected liver formed
dimers and multimers (14). Deletions or point mutation of
MATERIALS AND METHODS
Peptide Synthesis. Three peptides (Fig. 1B) were assembled
by fluorenylmethoxycarbonyl chemistry and purified by re-
versed-phase HPLC. Each peptide was Na-acetylated and
Ca-amidated. Crude peptide in 0.05% trifluoroacetic acid was
separated on an octyl-silica column [C8, Applied Biosystems,
250mm x 10mm (i.d.), 300-A pore size] by elution at 3 ml/min
over 50 min with a linear gradient of 20-42% acetonitrile in
0.05% trifluoroacetic acid. Peptide 812-49 was eluted at 32%
acetonitrile, 825-60(Y) at 34.5% acetonitrile, and 812-60(Y)
at 36% acetonitrile (monitored at 230 nm). The homogeneity
of the individual fractions was determined on an analytical
octyl-silica column. The expected mass of each peptide was
confirmed by electrospray ionization (ESI) mass spectrome-
try: peptide 812-49, m/z 4690.3 ± 1.0 (calcd. 4689.4); 825-
60(Y), m/z 4506.1 ± 0.8 (calcd. 4506.4), 812-60(Y), m/z
6034.1 ± 1.2 (calcd. 6033.7).
Circular Dichroic (CD) Spectroscopy. CD spectra were
recorded with an AVIV model 60DS CD spectrophotometer
using quartz cuvettes (10-mm path). Part (0.5-5 ,ul) of a stock
Abbreviations: ESI, electrospray ionization; HDAg, hepatitis delta
antigen; HDV, hepatitis delta virus.
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FIG. 1. Synthetic peptides from the multimer-forming domain of
HDAg. (A) Structural organization of HDAg. The lightly stippled
region is the multimer-forming domain (amino acid residues 12-60),
the solid regions are the RNA-binding domains (21), and the heavily
stippled region is the C-terminal extension of large HDAg. Hydro-
phobic residues contributing to the heptad repeat are shown in
boldface type. (B) Amino acid sequences of three HDAg peptides. A
tyrosine residue, (Y), was added after Lys60 to permit radioiodination.
solution of peptide in water was diluted to 200 ,l with
phosphate-buffered saline (PBS: 140 mM KCl/10 mM
NaCl/20 mM sodium phosphate, pH 7.1). Peptide concentra-
tions were determined by quantitative amino acid analysis. The
a-helicity was estimated (23) as [0]222/[6]max, where [O]m. iS
the maximal theoretical ellipticity at 222 nm calculated as
-39,500[1 - (2.57/n)] deg-cm2 dmol-1, where n is the number
of residues per chain. Thermal denaturation was monitored at
222 nm. Each solution was cooled to 5°C, allowed to equili-
brate for 5 min, and spectrally scanned twice with a 15-s
averaging time. This procedure was repeated at 5°C intervals
until the signal stopped changing, indicating that the structure
was fully denatured.
ESI Mass Spectrometry. ESI mass spectra were collected on
a Sciex Model API-III mass spectrometer (Thornhill, Ontario)
in the positive-ion mode. The sample was infused into the mass
spectrometer via a Harvard model 22 syringe pump. The
ion-spray needle was kept at 5300 V and the orifice potential
was held at 80 V. In the deuterium-exchange experiments (24)
each sample was lyophilized to or near dryness to minimize the
presence of H20. A solution of 5 ,M peptide in 2H20 (D20)
(pD 6.5) was infused at 2 ,ll/min into the enclosed ionization
chamber, which was constantly flushed with nitrogen at 4
liters/min. Under these conditions, exchange of hydrogen by
deuterium occurred only in the solution phase, and back
exchange of deuterium by hydrogen was negligible in the gas
phase. Data collection was begun within 12 s of dissolution.
The mass range of m/z 640-1150, containing selected charge
states of the molecular ion, was scanned repetitively with a step
size of 0.2 Da, a dwell time of 1.5 ms, and a total scan time of
3.4 s. The combined data from several charge states were used
to calculate the average molecular mass. The number of
hydrogens (Ht) remaining to be exchanged at time t was
calculated as the mass of the fully deuterated molecule minus
the observed mass at t. Calculation of the number of exchange-
able hydrogens and their first-order rate constant for a set of
hydrogens undergoing deuterium exchange at the same rate
has been described (24).
Size-Exclusion Chromatography. The apparent mass of the
812-60(Y) multimer was determined by comparison to the
masses of four globular protein standards: bovine serum
albumin, chicken ovalbumin, horse myoglobin, and cyto-
chrome c variant C102T. Samples were eluted from a TSK-
6000 size-exclusion column with PBS at 0.7 ml/min.
Solid-Phase Immunoassays. An enzyme-linked immunosor-
bent assay (ELISA) measured the binding of antibodies to
peptide adsorbed directly to a plastic surface. Solutions of
peptide (0.64 nM to 2 AM) in 50 mM sodium carbonate buffer
(pH 9.0) were incubated overnight at 4°C in quadruplicate
wells of a polystyrene microtiter plate. The plate was exten-
sively washed with PBS containing 0.05% Tween 20 detergent
and blocked with 10% fetal bovine serum in PBS for 25 min
at 37°C. Bound peptide was detected by incubation with a
human anti-HDAg serum diluted 1:500 in PBS and then with
horseradish peroxidase-conjugated guinea pig anti-human IgG
antibodies and o-phenylenediamine dichloride as substrate.
Absorbance was measured at 490 nm.
A sandwich radioimmunoassay (RIA) measured the binding
of radiolabeled polyclonal anti-HDAg antibodies to peptides
captured by anti-HDAg antibodies adsorbed to a plastic sur-
face. Duplicate wells of a poly(vinyl chloride) microtiter plate
were coated with human anti-HDAg serum (1:1000 dilution).
Peptide (0.64 nM to 2 ,uM) in PBS containing 5% fetal bovine
serum was added. The plate was incubated for 2 hr at 37°C and
washed with PBS containing 0.05% Tween 20. Bound peptide
was detected by adding 125I-labeled human polyclonal anti-
HDAg IgG (2 x 105 cpm per well), washing, and radioactivity
counting (25).
Rate-Zonal Ultracentrifugation. Peptides were layered onto
linear 6-20% (wt/wt) sucrose gradients and centrifuged for 20
hr at 36,000 rpm in a Beckman SW41 rotor. Fractions were
collected from the bottom of the gradient and tested for
immunoreactivity by ELISA.
Glutaraldehyde Crosslinking. The C-terminal tyrosine res-
idues of 812-60(Y) and 825-60(Y) were labeled with 1251 by
the chloramine-T method. A solution of the radiolabele'd
peptide in PBS containing 2% fetal bovine serum was
crosslinked for 3 min with 0.025-0.2% glutaraldehyde. The
sample was diluted with Laemmli's buffer, separated by SDS/
PAGE, and autoradiographed.
Peptide Inhibition ofHDAg Assembly. HDAg from the liver
of an acutely infected woodchuck was extracted into 4 M
guanidine hydrochloride, mixed with 10 ,uM peptide 812-
60(Y) or 825-60(Y), and dialyzed against PBS (14). The
dialysate was subjected to rate-zonal centrifugation in a linear
10-30% sucrose gradient for 18 hr at 35,000 rpm in an SW41
rotor. Fractions were collected from the bottom of the gradi-
ent and HDAg immunoreactivity was detected by RIA.
RESULTS AND DISCUSSION
Peptide Synthesis. Three peptides from the 12-60 region of
HDAg were synthesized (Fig. 1B). Peptide 812-49, consisting
of segments A and B, included the residues predicted by the
computer algorithm to form a coiled coil but lacked the 11
residues of segment C. Peptide 825-60(Y) contained segments
B and C and lacked the 13 residues of segment A. Peptide
812-60(Y) included segments A, B, and C. Segment B is
common to all three peptides, contains three heptads in which
the first and fourth heptad positions are occupied by five
leucines and one isoleucine, and is probably part of an a-helical
coiled coil. A tyrosine residue, (Y), was added to the C
terminus of peptides 825-60(Y) and 812-60(Y) to permit
radioiodination.
CD Spectroscopy. The a-helicity and the temperature at the
midpoint of thermal denaturation (Tm) of the peptides were
determined by CD spectroscopy. All three peptides had high
a-helicity in PBS at 5°C (Table 1 and Fig. 2A). The tatio of the
mean residue ellipticity of the negative bands near 222 nm and
208 nm ([0222]/[0208]) is an indicator of coiled-coil formation.
Values close to 1.0 indicate an a-helical coiled coil and values
near 0.8 indicate isolated a-helices (26). At 5°C this ratio was
0.98 for 812-60(Y), 0.93 for 812-49, and 0.88 for 825-60(Y).
At 37°C, this ratio was 0.94 for 812-60(Y), consistent'with
persistence of a coiled-coil structure. In contrast, at 370C this
ratio was only 0.79 for 812-49 and 0.76 for 825-60(Y),
inconsistent with a coiled-coil structure (Table 1 and Fig. 2B).
All three peptides showed protein-like thermal denaturation
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Table 1. CD spectroscopy of three synthetic peptides from human HDAg
Conc., 50C 370C
Peptide ,uM [0]222/[01208 [01222* a-Helicity, % [01222/[O]208 [01222* a-Helicity, %
825-60(Y) 32 0.88 -20,000 54 0.76 -13,600 37
812-49 26 0.93 -25,900 70 0.79 -16,700 45
812-60(Y) 15 0.98 -36,200 97 0.94 -31,300 84
*Degrees.cm2.dmol- 1.
profiles. At 37°C, peptide 612-60(Y) was 84% a-helical, but
the shorter peptides were <50% a-helical (Table 1 and Fig.
2A). For peptide 812-60(Y), the Tm value was much higher
(>80°C) and remained higher at a much lower concentration
(4 AM) than for the shorter peptides (Fig. 2C), indicating that
both segments A and C are involved in stabilizing its a-helical
structure. Since Tm increased with peptide concentration (Fig.
2C), each peptide is stabilized by self-association.
Deuterium Exchange. The stability of the a-helical multimer
formed by peptide 812-60(Y) was studied by determining the
kinetics of deuterium exchange. Specifically, the rates of
replacement of exchangeable hydrogen atoms by deuterium
were measured by ESI mass spectrometry. The lyophilized
peptide was dissolved in D2O (pD 6.5) and the increase in
mass due to deuterium exchange was monitored as a function
of time (Fig. 3A). Deuterium exchange of peptides 812-49 and
825-60(Y) was complete during the 12 s preceding measure-
ment of the first data point, indicating that these peptides are
only transiently a-helical at 25°C.
Of the 104 exchangeable hydrogens in the uncharged state
of peptide 812-60(Y), about 41 remained after 12 s, 29
remained after 9 min, and 22 remained after 30 min (Fig. 3A
and B). These results are consistent with the presence of four
kinetically distinct sets of hydrogens: a set of 63 that exchanged
very rapidly during the 12 s before the first data point was
obtained, a set of 7 that exchanged slowly (first-order rate
constant k = 5.7 x i0-4 s') over the next 9 min, a set of 12
that exchanged 2.4 times more slowly, and a set of 22 that had
not yet exchanged after 30 min, for a total of 41 slowly
exchanging hydrogens. If peptide 612-60(Y) were fully a-he-
lical, it would contain 44 NH peptide hydrogens participating
in a-helical hydrogen bonds [48 peptide bonds (none for Pro49)
minus 4 N-terminal NH peptide hydrogens that cannot form
a-helical hydrogen bonds]. Therefore, the a-helicity of peptide
612-60(Y) was estimated to be 41/44, or 93%, at 25°C as
measured by ESI mass spectrometry. For comparison, the
a-helicity of peptide 812-60(Y) was estimated to be 97% at
5°C and 84% at 37°C as measured by CD spectroscopy (Table
1). Thus these two completely different biophysical methods
provided very similar values for the a-helicity of the 812-60(Y)
multimer. Good agreement of a-helicity estimates by these two












Rate-Zonal Ultracentrifugation and Chemical Crosslink-
ing. Further evidence for the self-association of 612-60(Y) was
obtained by rate-zonal ultracentrifugation. Peptide 612-60(Y)
sedimented to the center of a linear 6-20% sucrose gradient
on centrifugation for 20 hr, but peptide 825-60(Y) remained
at the top of a similar gradient (Fig. 4A4). Thus 812-60(Y)
formed a large multimer but the shorter peptide did not. In
separate experiments, these two peptides were radiolabeled at
the C-terminal tyrosine residue and then chemically
crosslinked in the presence of a large quantity of heteroge-
neous serum proteins by brief exposure to low concentrations
of glutaraldehyde. During subsequent separation by SDS/
PAGE, crosslinked 812-60(Y) migrated as a ladder of discrete
multimers of increasing mass (Fig. 4A Inset). The largest
crosslinked multimer migrated with an apparent mass of 25
kDa, consistent with the presence of four or five 612-60(Y)
chains. Although both peptides were randomly crosslinked to
larger serum proteins, a similar protein ladder was not ob-
tained with crosslinked 825-60(Y).
Size-Exclusion Chromatography. Size-exclusion chroma-
tography confirmed that noncrosslinked 812-60(Y) formed a
multimer with an apparent mass of 30 kDa (data not shown),
which would correspond to a multimer of five 6-kDa chains.
The mass standards were globular proteins, but the 612-60(Y)
multimer is likely to have an elongated shape. Thus the
apparent mass of the multimer is probably higher than its
actual mass, suggesting that the multimer may actually be a
tetramer.
Peptide Inhibition ofHDAg Assembly. The ability of peptide
612-60(Y) to form multimers suggested that it might form a
complex with natural HDAg expressed during HDV infection.
To test this possibility, HDAg was extracted under denaturing
conditions from the liver of an HDV-infected woodchuck and
slowly renatured in the presence of 812-60(Y) or 625-60(Y)
(Fig. 4B). Under these conditions, HDAg normally forms
multimers that sediment at 15 S (14). This remained the case
when HDAg was renatured in the presence of 825-60(Y).
When renatured in the presence of 812-60(Y), however,
HDAg failed to form 15S multimers and sedimented below 7
S (Fig. 3B). Thus 812-60(Y) inhibited the formation ofHDAg
multimers. Since HDAg multimers are important for replica-
tion of HDV, 812-60(Y) or related peptides may have signif-
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FIG. 2. CD spectra of synthetic HDAg peptides. (A) CD spectra at 5°C in PBS, showing substantial helicity of all three peptides. (B) CD spectra
at 37°C. (C) Temperature at the midpoint of thermal denaturation (Tm) versus peptide concentration.
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FIG. 3. Deuterium exchange of 812-60(Y), 825-60(Y), and 812-49. (A) The number of exchangeable hydrogens (He) remaining is plotted versus
time. (B) ln(H,) is plotted from 0.2 to 9 min. The slope corresponds to a first-order rate constant of 5.7 x 10-4 s-1 and a half-life of 20 min. (C)
ln(Ht) is plotted from 9 to 30 min. The slope corresponds to a first-order rate constant of 2.4 x 10-4 S-1 and a half-life of 48 min.
icant antiviral activity if properly delivered to an HDV-
infected cell.
Antigenicity of HDAg Peptides. In previous studies, short
oligopeptides from the 12-60 region of HDAg demonstrated
onlyweak or inconsistent antigenic activity when tested against
panels of human anti-HD-positive antisera (25, 27). However,
all three HDAg peptides shown in Fig. 1 displayed substantial
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FIG. 4. Peptide 812-60(Y) self-associated into a multimer and
disrupted multimer formation by natural HDAg from the liver of an
infected woodchuck. (A) Rate-zonal ultracentrifugation of 812-60(Y)
and 825-60(Y) in a linear 6-20% sucrose density gradient. (Inset)
SDS/PAGE of 825-60(Y) (lanes 1-4) and 812-60(Y) (lanes 5-8)
following crosslinking with 0.025% (lanes 1 and 5), 0.05% (lanes 2 and
6), 0.1% (lanes 3 and 7), or 0.2% (lanes 4 and 8) glutaraldehyde. (B)
Peptide 812-60(Y), but not 625-60(Y), prevented formation of native
HDAg multimers during removal of guanidine hydrochloride from
extracts of HDV-infected woodchuck liver. After dialysis in the
presence of the indicated peptide, the liver extract was rate-zonally
ultracentrifuged through a linear 10-30% sucrose gradient. Arrows
indicate the positions of IgM (19 S) and IgG (7 S).
detected peptides adsorbed to polystyrene from a solution as
dilute as 2 ,uM for 612-49 and 825-60(Y) but 0.08 ,uM for
612-60(Y) (Fig. 5A). This 25-fold difference in immunoreac-
tivity was not due to different affinities of the peptides for
polystyrene, because equal amounts of radioiodinated 825-
60(Y) and 812-60(Y) were bound to the polystyrene. These
results indicate that both segmentA and segment C contribute
to the immunoreactivity of 812-60(Y).
In contrast to these ELISA results, only peptide 812-60(Y)
showed immunoreactivity in a sandwich RIA, in which peptide
bound by human anti-HDAg polyclonal antibodies adsorbed to
poly(vinyl chloride) was subsequently detected by binding of a
radioiodinated polyclonal antibody (Fig. SB). A peptide must
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FIG. 5. Immunoreactivity of synthetic HDAg peptides in two
solid-phase immunoassays. (A) Solid-phase ELISA for HDAg detec-
tion. A peptide adsorbed to polystyrene was detected by incubation
with human polyclonal anti-HDAg antibodies and then with horse-
radish peroxidase-conjugated anti-human IgG antibodies. (B) Solid-
phase sandwich RIA for HDAg detection. A peptide was bound by
human polyclonal anti-HDAg antibodies adsorbed to poly(vinyl chlo-
ride) and was detected by incubation with radioiodinated human
polyclonal anti-HDAg antibodies.
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have at least two epitopes to function as a bivalent ligand in this
sandwich RIA, while a peptide that displays only one epitope
can be immunoreactive in the ELISA. Peptide 612-60(Y) was
detected in the sandwich RIA at a concentration as low as 3.2
nM, but peptides 812-49 and 825-60(Y) were not detected
even at 2 ,uM. Thus only 812-60(Y) exhibited bivalent binding
to anti-HDAg antibodies from HDV-infected patients. Similar
results have recently been obtained with a murine monoclonal
antibody to HDAg (J.-G.W. and S.M.L., unpublished work).
Thus, this immunoreactivity of 812-60(Y) is likely to be due to
the formation of multimers.
Conclusion. In contrast to previous predictions (14, 19),
these results indicate that the 49-residue region from Gly12
through Lys6O of HDAg functions as a multimer-forming
domain of HDAg. The three-dimensional structure of this
domain remains to be determined, but it may resemble the
parallel four-helix structure of peptide variants of the GCN4
coiled coil (28) or the antiparallel four-helix structure of
melittin (29, 30). Thus the peptide 612-60(Y) may be another
example of a four-helix bundle, which has been a target of
rational protein design (31, 32).
HDAg specifically binds HDV RNA and regulates its rep-
lication (5, 10). In contrast to the basic-leucine zipper (bZip)
class of nucleic acid-binding proteins, the nucleic acid-binding
domain of HDAg is located C-terminal to the multimer-
forming coiled-coil domain (20) (Fig. 1A). It is likely that the
affinity of HDAg for viral RNA is influenced by its ability to
form multimers. It is also likely that multimer formation plays
an important role in the assembly of the HDV particle. The
ability of peptide 812-60 to interrupt self-association of HDAg
extracted from infected liver suggests that synthetic peptides,
if properly delivered to an infected cell, may have significant
antiviral activity. The enhanced immunoreactivity of 812-
60(Y) correlates with its ability to form multimers of four or
more chains and has significant practical implications for
development of improved diagnostic tests and possibly even
vaccines for prevention of HDV disease.
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